Fourth Quarter and Full Year End 2013 Financial Results Conference Call
|
|
- Lawrence Cain
- 5 years ago
- Views:
Transcription
1 Fourth Quarter and Full Year End 2013 Financial Results Conference Call February 27, 2014
2 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to, statements regarding guidance with respect to expected revenues, non-gaap cash earnings per share and adjusted cash flows from operations, organic growth, operating margin, integration-related activities and benefits, synergies, launches and approvals of products and assumptions with respect to guidance of Valeant Pharmaceuticals International, Inc. (the Company ). Forward-looking statements may be identified by the use of the words anticipates, expects, intends, plans, could, should, would, may, will, believes, estimates, potential, or continue and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes. Non-GAAP Information To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the company uses non-gaap financial measures that exclude certain items, such as amortization of inventory step-up, amortization of alliance product assets & property, plant and equipment step up, stock-based compensation step-up, contingent consideration fair value adjustments, restructuring, acquisition-related and other costs, In-process research and development, impairments and other charges, ("IPR&D"), legal settlements outside the ordinary course of business, the impact of currency fluctuations, amortization including intangible asset impairments and other non-cash charges, amortization and write-down of deferred financing costs, debt discounts and ASC (FSP APB 14-1) interest, loss on extinguishment of debt, (gain) loss on assets sold/held for sale/impairment, net, (gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-gaap financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-gaap financial measures, management intends to provide investors with a meaningful, consistent comparison of the company s core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP. Therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Note 1: The guidance in this presentation is only effective as of the date given, February 27, 2014, and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. 1
3 Agenda 1. Fourth Quarter & Year End 2013 Results 2. Operations Update 3. Financial Update 2
4 Fourth Quarter and Year End 2013 Results Q Y/Y % 2013 Y/Y % Product Sales $2.0 B 116% $5.6 B 72% Total Revenue $2.1 B 109% $5.8 B 66% Cash EPS $ % $ %* Adjusted Cash Flow from Operations $607 M 43% $1.8 B 38% * Excludes $66M dermatology divestitures, $45M milestone payment from GSK and $30M one-time non-cash Fx gain recorded in
5 2013 Organic Growth Same Store Sales Q Ex Generics FY 2013 Ex Generics Total U.S. -3% 14% -7% 10% ROW Developed 12% 12% 2% 7% Total Developed 0% 13% -5% 9% Emerging Markets 8% 8% 11% 11% Total 2% 12% 0% 10% Pro Forma Q Ex Generics FY 2013 Ex Generics Total U.S. 4% 12% -2% 7% ROW Developed 5% 5% 2% 1% Total Developed 4% 10% -1% 6% Emerging Markets 13% 13% 12% 12% Total 6% 11% 2% 7% Note: Generics excluded include Zovirax Franchise, Retin-A Micro, BenzaClin 4
6 Bausch + Lomb Performance Same Store Sales Growth Q (Since Close) U.S. 17% 16% ROW Developed 1% 2% Total Developed Markets 9% 9% Total Emerging Markets 16% 15% Total Company 10% 10% 5
7 Bausch + Lomb U.S. Performance Same Store Sales Growth Q Contact Lens 14% Surgical 24% Rx 16% Consumer 11% Generics 31% Total U.S 17% 6
8 Operational Highlights - Top Performing Business Units Business Unit 4Q Run Rate Y/Y Growth Asia $1.0 B >300% Neurology & Other $1.0 B >20% Aesthetics $400 M >300% Russia $400 M >300% Canada $400 M >10% Poland $250 M >30% Oral Health $125 M >20% 7
9 Adjusted Cash Flow From Operations $607 $345 $423 $408 Excluded Items: Legal Settlements Restructuring/Acquisition Related Costs Tax Benefit from Stock Options 1st Qtr 2nd Qtr 3rd Qtr 4th Qtr Total 2013 Adjusted Cash Flow from Operations = $1.8 Billion 8
10 2013 Performance v. Guidance Original Expectations Final Results Revenue $4.4 - $4.8 billion Revenue $5.8 billion Cash EPS $ $5.65 Cash EPS $6.24 $1.5 - $1.75 billion in Adjusted Cash Flow from Operations $1.8 billion in Adjusted Cash Flow from Operations Organic Growth*: 10% same store sales 7% pro forma * Generics excluded include Zovirax Franchise, Retin-A Micro, BenzaClin 9
11 Update on 2014 Expected Product Launches Product Business Unit Description Estimated Launch Date Bensal Derm Rx Topical treatment for the inflammation and irritation associated with many forms of dermatitis Launched CeraVe Baby Line Consumer OTC Moisturizer Launched envista Inserter Surgical Latest enhancements Approved and Launched Ossix Plus Oral Health Dental Membrane Launched Bausch+Lomb Ultra Contact Lens Silicone Hydrogel monthly disposable contact lenses Luzu Derm Rx Topical antifungal approved for tinea cruris, corporis, and pedis Neotensil Aesthetics Topical product that reduces the appearance of under-eye bags within one hour Launched To Be Launched 3/31 To Be Launched 3/31 Peroxiclear Consumer Hydrogen peroxide-based contact lens solution To Be Launched Late March Retin-A Micro.08% Derm Rx Topical medication to treat Acne Approved and To Be Launched June Victus Enhancements Surgical Launch of multiple VICTUS enhancements FDA corneal incision clearance Feb 14/ FDA lens fragmentation estimated 2H of 2014 Jublia Derm Rx Topical antifungal for onychomycosis 2H 2014 (pending FDA approval) Trulign ranges Surgical Broader range of powers Q2 BioTrue Oneday for Presbyopia Contact Lens Daily Contact Lens Launching regionally in 2014 Hyaluronic Acid for Lips Aesthetics Small-particle filler Q
12 Update on R&D Projects Program Status Result Next Steps Mapracorat Phase 3 Unsuccessful Discontinued Brimonidine (Eye Whitener) Phase 3 Successful Submit in 2015 Latanoprostene bunod (Glaucoma) Phase 3 Pending Receive data 2H 2014 MIM-D3 (Dry Eye) Phase 3 Pending Receive data Q Jublia Submitted Pending Launch 2H 2014 Retin-A Micro.08% snda Approved Launch in June Onexton (Acne) Phase 3 Submitted PDUFA date - Nov 2014 Bausch + Lomb Ultra Toric / Multifocal 510k Cleared Design Validation BioTrue Multifocal 510k Cleared Design Validation 11
13 Emphasis on Sales Professionals Total Sales Professionals % of Headcount (Excl Mfg) Total U.S 1,445 73% Asia 1,900 87% Europe 2,300 68% Latin America % Total Company 6,680 72% 12
14 Update on Aesthetic and Oral Health Expansions Aesthetics Increase facial injectable sales professionals in Q Total facial injectables sales force ~200 Integration of Solta complete Launch Neotensil March 31, 2014 Launch of Obagi 360 system OraPharma Completed sales force expansion by ~50% Recently launched Ossix Plus (dental membrane) in U.S. market Doubled the market share for Xerese (within dental market segment) from Dec Dec 2013 through sales promotion by OraPharma team 13
15 Financial Update Howard Schiller
16 Financial Summary Q Q FY 2013 FY 2012 Product Sales $2.0B $942M $5.6M $3.3B Ongoing Service/Alliance Revenue $32M $44M $129M $147M Total Revenue excl. one-timers $2.1B $986M $5.8B $3.4B One-time items N/A N/A N/A $45M Total Revenue $2.1B $986M $5.8B $3.5B Cost of Goods Sold% 2 (% of product sales) 26% 25% 25% 24% SG&A% 2 (% of total revenue) 22% 20% 22% 21% R&D Expense $60M $20M $157M $79M EBITA Margin 1 (% of total revenue) 49% 53% 50% 53% Cash EPS (Reported) $2.15 $1.22 $6.24 $4.51 w/o one-time items $2.15 $1.22 $6.24 $4.14 Adjusted Cash Flow from Operations $607M $423M $1.8B $1.3B Fully Diluted Share Count 341M 312M 327M 313M 1 Excludes all non-operating expenses 2 Excludes adjustments per Press Tables 2a & 2b 15
17 Q Outlook Cash EPS expected to be 40% / 60% 1H vs. 2H Q1 expected to be lowest quarter; Q4 expected to be highest quarter Generic impact greatest in Q1 Continued impact from Zovirax franchise & RAM New generics Wellbutrin XL (Canada) & Vanos (U.S.) Same store organic growth expected to be negative in Q1 due to generic headwinds, but positive in Q2 and for full year SG&A as a % of revenue is expected to increase in Q1 Launch costs from Luzu, Neotensil, Bausch + Lomb Ultra Expansion of Oral Health and Aesthetics sales forces Completion of late stage R&D programs ~$200m spend expected in 1H Fx impact Movement in currencies to negatively impact Q1 by ~$0.04 per share since budget approved in November 16
18 Fx Exposure Summary Currency % of Total Revenue Change since Budget U.S. ~50% N/A Euro ~15% 0.0% Russian Ruble ~5% -11% Canadian Dollar ~5% -7% Polish Zloty ~5% 2% Japanese Yen ~4% -5% All Others Combined - Turkish Lira - Argentinian Peso - Brazilian Real - Australian Dollar - All others ~20% -10% -33% -5% -5% N/A 17
19 Financial Guidance for % over 2013 Revenue $8.2 - $8.6 billion ~40% Cash EPS $ $8.75 ~40% Adjusted Cash Flow from Operations $2.4 - $2.6 billion ~40% Includes Solta Does not include PreCision will update after close Fx Exposure ~$0.15 per share negative Cash EPS impact since budget was approved in November Significant Fx changes in a number of countries, including Russia, Canada, Japan, Australia, Brazil, Turkey, Argentina See Note 1 regarding guidance 18
20 Fourth Quarter and Full Year End 2013 Financial Results Conference Call February 27, 2014
2014 Financial Guidance Conference Call
2014 Financial Guidance Conference Call January 7, 2014 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including,
More informationValeant Pharmaceuticals International, Inc. First Quarter 2015 Financial Results Conference Call April 29, 2015
Valeant Pharmaceuticals International, Inc. First Quarter 2015 Financial Results Conference Call April 29, 2015 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation
More informationValeant Pharmaceutical International, Inc. Jefferies 2014 Global Healthcare Conference
Valeant Pharmaceutical International, Inc. Jefferies 2014 Global Healthcare Conference November 19, 2014 1 Forward-Looking Statements This communication may contain forward-looking statements within the
More informationSecond Quarter 2013 Financial Results Conference Call
Second Quarter 2013 Financial Results Conference Call August 7, 2013 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements,
More informationFirst Quarter 2013 Financial Results Conference Call
First Quarter 2013 Financial Results Conference Call May 2, 2013 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements,
More informationFirst Quarter 2012 Financial Results Conference Call
First Quarter 2012 Financial Results Conference Call May 3, 2012 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements,
More informationThird Quarter 2014 Financial Results Conference Call
Third Quarter 2014 Financial Results Conference Call October 20, 2014 Forward-looking Statements This communication may contain forward-looking statements within the meaning of the Private Securities Litigation
More informationThird Quarter 2012 Financial Results Conference Call
Third Quarter 2012 Financial Results Conference Call November 2, 2012 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements,
More informationValeant Pharmaceuticals International, Inc. Fourth Quarter and Full Year 2015 Supplemental Information
Valeant Pharmaceuticals International, Inc. Fourth Quarter and Full Year Supplemental Information Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may
More informationValeant Pharmaceuticals International, Inc Annual Meeting. May 19, 2015 Laval, Quebec, Canada
Valeant Pharmaceuticals International, Inc. 2015 Annual Meeting May 19, 2015 Laval, Quebec, Canada Introductions Board of Directors Ronald Farmer Colleen Goggins Robert Ingram (Lead Director) Anders Lönner
More informationValeant Pharmaceutical International, Inc.
Valeant Pharmaceutical International, Inc. 2015 J.P. Morgan Healthcare Conference Howard Schiller EVP and Chief Financial Officer Dr. Ari Kellen EVP and Company Group Chairman January 13, 2015 Forward-looking
More information2018 Annual Meeting of Shareholders April 30, 2018 Laval, Quebec
2018 Annual Meeting of Shareholders April 30, 2018 Laval, Quebec Forward-Looking Statements Forward-Looking Statements This presentation contains forward-looking information and statements, within the
More informationQ3 Fiscal Year 2019 Financial Highlights
Q3 Fiscal Year 2019 Financial Highlights For the quarter ended October 31, 2018 November 29, 2018 Forward Looking Statements Certain statements in this communication may contain forward looking statements
More informationValeant Pharmaceuticals International, Inc. Q Financial Results July 23, 2015
Valeant Pharmaceuticals International, Inc. Q2 2015 Financial Results July 23, 2015 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute forward-looking
More informationQ1 Fiscal Year 2019 Financial Highlights
Fiscal Year 2019 Financial Highlights For the quarter ended April 30, 2018 May 31, 2018 Forward-Looking Statements Certain statements in this communication may contain forward-looking statements within
More informationBAUSCH HEALTH COMPANIES INC. ANNOUNCES SECOND-QUARTER 2018 RESULTS
Investor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-0617 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationValeant Pharmaceuticals International, Inc. February 23, 2015
Valeant Pharmaceuticals International, Inc. February 23, 2015 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements,
More informationEndo International plc
Endo International plc Q2 2015 Earnings Report August 10, 2015 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private
More informationForward-Looking Statements
2Q 17 Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, forwardlooking statements ), including,
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationForward-Looking Statements
1Q 18 Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, forward-looking statements ), including,
More informationBe decisive, stay balanced, and always find ways to grow. A SIMPLE PHILOSOPHY 2014 ANNUAL REPORT
Be decisive, stay balanced, and always find ways to grow. A SIMPLE PHILOSOPHY 2014 ANNUAL REPORT company overview Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical
More informationMcKesson Corporation Q2 Fiscal 2019 Financial Performance. Financial Results and Company Highlights October 25, 2018
McKesson Corporation Q2 Fiscal 2019 Financial Performance Financial Results and Company Highlights October 25, 2018 Forward-Looking Statements Some of the information in this presentation is not historical
More information2017 Full Year Results. Tuesday 21 November 2017
2017 Full Year Results Tuesday 21 November 2017 Disclaimer Certain information included in the following presentation is forward looking and involves risks, assumptions and uncertainties that could cause
More information2Q 18. Financial Results
2Q 18 Financial Results Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, forward-looking
More informationBAUSCH HEALTH COMPANIES INC. ANNOUNCES THIRD-QUARTER 2018 RESULTS
Investor Contact: Media Contact: Arthur Shannon Lainie Keller arthur.shannon@bauschhealth.com lainie.keller@bauschhealth.com (514) 856-3855 (908) 927-0617 (877) 281-6642 (toll free) BAUSCH HEALTH COMPANIES
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationForward-Looking Statements
4Q & FY 2017 Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, forward-looking statements
More informationValeant s Acquisition of Medicis: Creating a Global Leader in Dermatology September 4, 2012
Valeant Pharmaceuticals International, Inc. Valeant s Acquisition of Medicis: Creating a Global Leader in Dermatology September 4, 2012 Forward-Looking Statements This presentation contains forward-looking
More informationThe Cooper Companies Announces Fourth Quarter and Full Year 2017 Results
December 7, 2017 The Cooper Companies Announces Fourth Quarter and Full Year 2017 Results PLEASANTON, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE:COO) today announced financial
More informationTeva Pharmaceutical Industries Ltd. Q August 2, 2018
Teva Pharmaceutical Industries Ltd. Q2 2018 August 2, 2018 Cautionary Note Regarding Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private
More informationEndo International plc
Endo International plc Q1 2015 Earnings Report May 11, 2015 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private
More information(Unaudited) Reconciliation GAAP to Non-GAAP (In thousands) Pro Forma As Adjusted. Pro Forma Adjustments. Pro Forma As Adjusted. Pro Forma Adjustments
Supplemental Presentation of Selected Quarterly Non-GAAP Financial Information for Fiscal Years 2014-2015, Including Proforma Related to Automotive Business Divesture and Reconciliation to GAAP As announced
More informationWalgreens Boots Alliance Fiscal year end 2015 and 4Q earnings conference call. 28 October 2015
Walgreens Boots Alliance Fiscal year end 2015 and 4Q earnings conference call 28 October 2015 Fiscal year end 2015 and 4Q earnings call agenda Topic Introduction & Safe Harbor Business Overview Financial
More informationForward-Looking Statements
3Q 17 Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, forwardlooking statements ), including,
More informationFourth Quarter and Fiscal 2016 Results. 20 October 2016
Fourth Quarter and Fiscal 2016 Results 20 October 2016 Safe harbor and non-gaap Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that
More informationEndo International plc
Endo International plc UBS Global Healthcare Conference May 21, 2014 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of
More informationCisco Systems Inc. Q1 FY 03 Conference Call November 6, 2002
Cisco Systems Inc. Q1 FY 03 Conference Call November 6, 2002 2002, Cisco Systems, Inc. All rights reserved. 1 Cisco Forward-Looking Statements This presentation may contain projections or other forward-looking
More information2Q 2017 Highlights and Operating Results
2Q 2017 Highlights and Operating Results July 25, 2017 1 2Q 2017 Highlights and Operating Results Table of Contents Page(s) 1 Sales Overview and Highlights 4-5 2 NSS Overview 6-7 3 EES Overview 8-9 4 UPS
More informationMcKesson Corporation Fiscal 2018 Financial Performance Fiscal 2019 Annual Outlook. Financial Results and Company Highlights May 24, 2018
McKesson Corporation Fiscal 2018 Financial Performance Fiscal 2019 Annual Outlook Financial Results and Company Highlights Forward-Looking Statements Some of the information in this presentation is not
More informationCFO COMMENTARY Q4 FY 2018
Q4 FY 2018 FINANCIAL INFORMATION AND CONFERENCE CALL Please see the accompanying earnings press release available at www.scansource.com in the Investor Relations section. The information included in this
More informationQ3 FY16 FINANCIAL RESULTS CONFERENCE CALL May 10, 2016 at 5:00 pm ET
Q3 FY16 FINANCIAL RESULTS CONFERENCE CALL May 10, 2016 at 5:00 pm ET SAFE HARBOR This presentation may contain certain comments, which are forward-looking statements that involve plans, strategies, economic
More information4Q 2017 Highlights and Operating Results
4Q 2017 Highlights and Operating Results January 30, 2018 1 4Q 2017 Highlights and Operating Results Table of Contents Page(s) 1 Sales Overview 4-8 2 Financial Performance Trends 9-16 3 Leverage Metrics
More information1Q 2018 Highlights and Operating Results
1Q 2018 Highlights and Operating Results April 26, 2018 1 Table of Contents Page(s) 4 Announced Agreements to Acquire Australia and New Zealand Security Businesses 5-9 Sales Overview 10-17 Financial Performance
More information2017 Annual Meeting Of Shareholders. MAY 2, 2017 Laval, Quebec, CANADA
2017 Annual Meeting Of Shareholders MAY 2, 2017 Laval, Quebec, CANADA Introductions BOARD OF DIRECTORS Joseph C. Papa Chairman Richard U. DeSchutter Dr. Frederic N. Eshelman D. Robert Hale Dr. Argeris
More informationQuarterly Update FY17 Fourth Quarter. November 9, 2017
Quarterly Update FY17 Fourth Quarter November 9, 2017 1 Johnson Controls plc. November 9, 2017 Johnson Controls International plc Cautionary Statement Regarding Forward-Looking Statements Johnson Controls
More informationZimmer Biomet Reports Second Quarter 2016 Financial Results
July 28, 2016 Zimmer Biomet Reports Second Quarter 2016 Financial Results -- Net Sales of $1.934 billion represent an increase of 65.6% over the prior year period, and an increase of 4.5% on an adjusted
More informationQ4 & Full Year 2017 Financial Results
Exhibit 99.2 Q4 & Full Year 2017 Financial Results February 6, 2018 Legal Notices Forward-Looking Statements This presentation and the oral remarks made in connection herewith may contain forward-looking
More informationFinancial Results for Q January 24, 2019
Financial Results for Q4 2018 January 24, 2019 SAFE HARBOR This presentation contains forward-looking statements regarding Teradyne s future business prospects, results of operations, market conditions,
More information3 rd Quarter Fiscal 2019
3 rd Quarter Fiscal 2019 SUPPLEMENTAL INFORMATION December 19, 2018 SAFE HARBOR STATEMENT Cautionary Statement Regarding Forward Looking Statements Statements in this presentation that are not historical,
More information4Q 2018 Highlights and Operating Results. Products. Technology. Services. Delivered Globally.
4Q 2018 Highlights and Operating Results Products. Technology. Services. Delivered Globally. Table of Contents Page 3 Safe Harbor Statement and Non-GAAP Financial Measures 4 Sales Overview 9 Overview of
More informationThe Cooper Companies Announces Third Quarter 2008 Results
The Cooper Companies Announces Third Quarter 2008 Results PLEASANTON, Calif., Sep 4, 2008 (GlobeNewswire via COMTEX News Network) -- The Cooper Companies, Inc. (NYSE:COO) today announced financial results
More informationFinancial results for Q January 26, 2017
Financial results for Q4 2016 January 26, 2017 SAFE HARBOR This presentation contains forward-looking statements regarding Teradyne s future business prospects, results of operations, market conditions,
More informationUnifi, Inc. Second Quarter Ended December 24, 2006 Conference Call
Unifi, Inc. Second Quarter Ended December 24, 2006 Conference Call Cautionary Statement Certain statements included herein contain forward-looking statements within the meaning of federal securities laws
More informationAastra Reports Second Quarter Financial Results
PRESS RELEASE For Immediate Release Aastra Reports Second Quarter Financial Results TORONTO, ONTARIO (July 27, 2006) -- Aastra Technologies Limited - (TSX: AAH ) today announced its unaudited financial
More informationPRELIMINARY RESULTS February 2017
PRELIMINARY RESULTS 2016 23 February 2017 Nicandro Durante Chief Executive Important notice This presentation in relation to British American Tobacco p.l.c. ( BAT ) and its subsidiaries (collectively,
More informationSecond Quarter 2018 Earnings Presentation May 8, 2018
Second Quarter 2018 Earnings Presentation May 8, 2018 Cautionary statements This presentation contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of
More information2018 Full Year Results 20 November 2018
2018 Full Year Results 20 November 2018 Disclaimer Certain information included in the following presentation is forward looking and involves risks, assumptions and uncertainties that could cause actual
More informationTeradyne, Inc. Certain Non-GAAP financial measures discussed during the Third Quarter of 2011 Earnings Conference Call October 2011
Teradyne, Inc. Certain Non-GAAP financial measures discussed during the Third Quarter of 2011 Earnings Conference Call October 2011 On the Company s earnings conference call on October 27, 2011, the following
More informationFOURTH QUARTER & FULL YEAR 2018 EARNINGS CONFERENCE CALL. February 13, 2019
FOURTH QUARTER & FULL YEAR 2018 EARNINGS CONFERENCE CALL February 13, 2019 Overview Fourth quarter 2018 net revenue increased 13.3% o Organic growth of net revenue was 7.1% US organic growth was 6.3% International
More informationEndo Health Solutions
Endo Health Solutions 3Q 2013 Earnings Report and A Compelling Combination: Endo Health Solutions and Paladin Labs November 5, 2013 Offer Language Disclosures This communication is not intended to and
More informationCFO Commentary. Third Quarter. Third-quarter diluted earnings per. share increased 33% year over year; non- GAAP diluted. earnings per share
Third Quarter CFO Commentary As reflected in our earnings release, there are a number of items that impact the comparability of our results with those in the trailing quarter and prior quarter of last
More informationTeva Pharmaceutical Industries Ltd. Fourth Quarter 2018 Results February 13, 2019
Teva Pharmaceutical Industries Ltd. Fourth Quarter 2018 Results February 13, 2019 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More informationSealed Air Reports Fourth Quarter and Full Year 2018 Results
Exhibit 99.1 Sealed Air Corporation 2415 Cascade Pointe Blvd. Charlotte, NC 28208 For release: February 7, 2019 Sealed Air Reports Fourth Quarter and Full Year 2018 Results Solid year-over-year sales and
More informationMondelēz International Q Results. July 27, 2016
Mondelēz International Q2 2016 Results July 27, 2016 1 Forward-Looking Statements This presentation contains a number of forward-looking statements. Words, and variations of words, such as will, expect,
More informationFOURTH QUARTER 2016 EARNINGS RELEASE January 31, 2017
FOURTH QUARTER 2016 EARNINGS RELEASE January 31, 2017 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments
More informationFiscal 2017 First Quarter Results. 5 January 2017
Fiscal 2017 First Quarter Results 5 January 2017 Safe harbor and non-gaap Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that are not
More informationFirst Quarter 2016 Business Update
Focused. First Quarter 2016 Business Update Innovative. Investor Presentation April 27, 2016 Performance Driven. Disclaimer Statement Regarding Safe Harbor For Forward-Looking Statements This presentation
More informationCIRCOR Reports Fourth-Quarter and Year-End 2018 Financial Results
CIRCOR Reports Fourth-Quarter and Year-End 2018 Financial Results February 27, 2019 BURLINGTON, Mass.--(BUSINESS WIRE)--Feb. 26, 2019-- CIRCOR International, Inc. (NYSE: CIR), a leading provider of flow
More informationQ4 AND FY 2015 FINANCIAL RESULTS CONFERENCE CALL August 20, 2015 at 5:00 pm ET
Q4 AND FY 2015 FINANCIAL RESULTS CONFERENCE CALL August 20, 2015 at 5:00 pm ET SAFE HARBOR This presentation may contain certain comments, which are forward-looking statements that involve plans, strategies,
More informationMylan Q EARNINGS November 5, Q Earnings All Results are Unaudited
Mylan Q3 EARNINGS November 5, Q3 Earnings All Results are Unaudited Forward-Looking Statements This presentation contains forward-looking statements. These statements are made pursuant to the safe harbor
More information2017 Investor Day. Reconciliation of GAAP to Non-GAAP Financial Measures. About Non-GAAP Financial Measures
2017 Investor Day Reconciliation of GAAP to Non-GAAP Financial Measures About Non-GAAP Financial Measures To supplement Cimpress' consolidated financial statements presented in accordance with U.S. generally
More informationFINANCIAL OVERVIEW AL M I S T Y S Y N
FINANCIAL OVERVIEW AL MISTYSYN SENIOR VICE PRESIDENT, FINANCE & CHIEF FINANCIAL OFFICER Forward-Looking Statement The presentations today will contain certain forward-looking statements," within the meaning
More informationEndo International plc
Endo International plc Q2 2017 Earnings Report August 8, 2017 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward looking statements within the meaning of the Private
More informationQ3 FY 2015 FINANCIAL RESULTS CONFERENCE CALL April 30, 2015 at 5:00 pm ET
Q3 FY 2015 FINANCIAL RESULTS CONFERENCE CALL April 30, 2015 at 5:00 pm ET SAFE HARBOR This presentation may contain certain comments, which are forward-looking statements that involve plans, strategies,
More informationSafe Harbor Statement
January 3, 2018 Safe Harbor Statement Statements in this presentation that are not historical, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation
More informationNew revenue accounting standard (ASC 606) and FY18 guidance
New revenue accounting standard (ASC 606) and FY18 guidance January 11, 2018 Gary E. Bischoping Jr., Chief Financial Officer Magnus Momsen, Chief Accounting Officer J. Michael Bruff, Vice President Investor
More informationFY 2017 Third Quarter Earnings Call
FY 2017 Third Quarter Earnings Call July 27, 2017 Improving the experience of a world in motion Forward Looking Statement Adient has made statements in this document that are forward-looking and, therefore,
More informationTHIRD QUARTER 2016 CONFERENCE CALL AND WEBCAST. November 1, 2016
THIRD QUARTER 2016 CONFERENCE CALL AND WEBCAST November 1, 2016 AGENDA Introduction Business Overview Financial Overview Roger Hendriksen Director, Investor Relations Jeff Edwards Chairman and Chief Executive
More informationQ Financial Results. October 25, 2018
Q3 2018 Financial Results October 25, 2018 Legal Notices Forward-Looking Statements This presentation and the oral remarks made in connection herewith may contain forward-looking statements within the
More informationAdvanced Flow Solutions Energy Fluid Handling. Fourth Quarter Investor Review. Presented February 28, 2018
Advanced Flow Solutions Energy Fluid Handling Fourth Quarter 2017 Investor Review Presented February 28, 2018 1 Safe Harbor This presentation contains forward-looking statements within the meaning of Section
More informationFiscal 2018 Second Quarter Earnings Call Presentation February 2, 2018
Fiscal 2018 Second Quarter Earnings Call Presentation February 2, 2018 Safe Harbor Statement Certain statements in this presentation may be forward-looking in nature, or "forward-looking statements" within
More informationINTERIM RESULTS PRESENTATION. 27 th July 2017
INTERIM RESULTS PRESENTATION 27 th July 2017 INTERIM RESULTS PRESENTATION 27 th July 2017 NICANDRO DURANTE CEO Important notice This presentation in relation to British American Tobacco p.l.c. ( BAT )
More informationCADENCE REPORTS FOURTH QUARTER AND FISCAL YEAR 2017
CADENCE REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 CADENCE DESIGN SYSTEMS, INC. CFO COMMENTARY January 31, 2018 Q4 2017 Key Takeaways Strong, consistent financial results for Q4 with key metrics meeting
More informationQ Financial Results. July 22, 2010
Q2 2010 Financial Results July 22, 2010 Q2 2010 Non-GAAP Results Q2 10 Q2 09 Y/Y % growth Q1 10 Billings (1) $90M $69M 31% $79M Revenue $76M $61M 24% $70M Non-GAAP Gross Margin (%) (2) 74% 74% -- 73% Non-GAAP
More informationEndo Health Solutions
Endo Health Solutions 4Q 2013 Earnings Report and Announcing The New Endo February 28, 2014 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements
More informationFiscal 2018 Second Quarter
Fiscal 2018 Second Quarter If you can read this Click on the icon to choose a Results picture or Reset the slide. To Reset: Right click on the slide thumbnail and select reset slide or choose the Reset
More informationResults for Q3 Fiscal 2019
Results for Q3 Fiscal 2019 Earnings Announcement: January 30, 2019 (Quarter Ended December 31, 2018) Risks and Non-GAAP Disclosures This presentation contains forward-looking statements within the meaning
More informationMattel, Inc. Earnings Conference Call Fourth Quarter 2016 (Unaudited Results)
Mattel, Inc. Earnings Conference Call Fourth Quarter 2016 (Unaudited Results) J A N U A R Y 2 5, 2 0 1 7 C H R I S T O P H E R S I N C L A I R C H I E F E X E C U T I V E O F F I C E R R I C H A R D D
More informationSECOND QUARTER 2014 EARNINGS CALL SUPPLEMENTAL MATERIALS
SECOND QUARTER 2014 EARNINGS CALL SUPPLEMENTAL MATERIALS July 29, 2014 2013 FIS and/or its subsidiaries. All Rights Reserved. Agenda TOPIC Second Quarter 2014 Highlights Operations Review Financial Summary
More informationItems impacting the first quarter of fiscal 2011 consisted of the following:
Non-GAAP Financial Information In addition to disclosing financial results that are determined in accordance with generally accepted accounting principles in the United States ( GAAP ), the Company also
More informationCommScope Holding Company, Inc. Condensed Consolidated Statements of Operations (Unaudited -- In thousands, except per share amounts)
Condensed Consolidated Statements of Operations (Unaudited -- In thousands, except per share amounts) Three Months Ended March 31, 2018 2017 Net sales $ 1,120,517 $ 1,137,285 Operating costs and expenses:
More informationElectrical Products Group Conference May 23, Greg Hayes Chairman & CEO
Electrical Products Group Conference May 23, 2017 Greg Hayes Chairman & CEO Note: All results and expectations in this presentation reflect continuing operations unless otherwise noted. Cautionary Statement:
More informationMylan: Q EARNINGS August 8, Q Earnings All Results are Unaudited
Mylan: Q2 2018 EARNINGS August 8, 2018 Q2 2018 Earnings All Results are Unaudited Forward-Looking Statements This presentation contains forward-looking statements. These statements are made pursuant to
More informationMattel, Inc. Earnings Conference Call Third Quarter 2016 (Unaudited Results)
Mattel, Inc. Earnings Conference Call Third Quarter 2016 (Unaudited Results) O C T O B E R 1 9, 2016 C H R I S T O P H E R S I N C L A I R C H I E F E X E C U T I V E O F F I C E R R I C H A R D D I C
More informationA X A L T A C O A T I N G S Y S T E M S Q4 & FULL YEAR 2015 FINANCIAL RESULTS FEBRUARY 10, 2016
A X A L T A C O A T I N G S Y S T E M S Q4 & FULL YEAR 2015 FINANCIAL RESULTS FEBRUARY 10, 2016 Legal Notices Forward-Looking Statements This presentation and the oral remarks made in connection herewith
More informationFIRST QUARTER 2019 EARNINGS CONFERENCE CALL FEBRUARY 28, 2019
FIRST QUARTER 2019 EARNINGS CONFERENCE CALL FEBRUARY 28, 2019 Safe harbor FORWARD-LOOKING STATEMENTS This presentation contains certain forward-looking information within the meaning of the Private Securities
More information2018 SECOND QUARTER FINANCIAL RESULTS
2018 SECOND QUARTER FINANCIAL RESULTS July 30, 2018 0 SAFE HARBOR STATEMENT The 2018 second quarter news release, conference call webcast, and the following slides contain forward-looking statements. The
More informationQ2 Results 2010 Presentation to Investors & Analysts. 21 st July 2010
1 Q2 Results 2010 Presentation to Investors & Analysts 21 st July 2010 Julian Heslop Chief Financial Officer 2 Financial summary Turnover Operating profit* EPS Free cash flow Q2 10 H1 10 m m 7,025 14,382
More information